MicroRNA therapeutics for cardiac regeneration

Zhiyong Lei, Joost P G Sluijter, Alain van Mil*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

It is estimated that a typical myocardial infarction results in the loss of approximately one billion functional cardiomyocytes, which are replaced by a non-contractile fibrous scar, eventually leading to heart failure. The currently available surgical, drug, and device-based therapies cannot reverse the loss of functional myocardium, which is the fundamental cause of the problem. As a result of this lack of an available medical solution, heart failure has evolved into a global epidemic. Therefore, the development of regenerative therapeutic strategies to halt the progression of ischemic heart disease to advanced heart failure has become one of the most urgent medical needs of this century. This review first addresses the extremely limited endogenous regenerative capacity of the mammalian heart, and the benefits and limitations of stem cell-based therapies for cardiac repair. Then it discusses the known roles of microRNAs after cardiac injury and the possibility of employing microRNAs to enhance cardiac regeneration.

Original languageEnglish
Pages (from-to)441-451
Number of pages11
JournalMini-reviews in medicinal chemistry
Volume15
Issue number6
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Cardiac progenitor cells
  • Cardiomyocytes
  • Cardiovascular disease
  • Heart failure
  • MicroRNA
  • Regeneration
  • Stem cells
  • Transplantation

Fingerprint

Dive into the research topics of 'MicroRNA therapeutics for cardiac regeneration'. Together they form a unique fingerprint.

Cite this